P. Chatelain

发表

Pharmacogenomics of insulin-like growth factor-I generation during GH treatment in children with GH deficiency or Turner syndrome

A. Stevens, P. Clayton, L. Tatò, 2013, The Pharmacogenomics Journal.

Pediatric perspective on pharmacogenomics.

R. Donn, A. Stevens, D. Hanson, 2013, Pharmacogenomics.

Combination of autoantibody markers and risk for development of type 1 diabetes: results from a large french cohort of family members.

B. Estour, P. Chatelain, S. Halimi, 2002, Diabetes & metabolism.

Human growth is associated with distinct patterns of gene expression in evolutionarily conserved networks

A. Stevens, D. Hanson, P. Clayton, 2013, BMC Genomics.

Network analysis: a new approach to study endocrine disorders.

R. Donn, A. Stevens, D. Hanson, 2013, Journal of molecular endocrinology.

Gene expression signatures predict response to therapy with growth hormone

M. Maghnie, G. Binder, A. Stevens, 2019, The Pharmacogenomics Journal.

Effect of summer daylight exposure and genetic background on growth in growth hormone-deficient children

C. Knight, A. Stevens, P. Clayton, 2015, The Pharmacogenomics Journal.

Derivation and validation of a mathematical model for predicting the response to exogenous recombinant human growth hormone (GH) in prepubertal children with idiopathic GH deficiency. KIGS International Board. Kabi Pharmacia International Growth Study.

M. Ranke, P. Chatelain, K. Albertsson-Wikland, 1999, The Journal of clinical endocrinology and metabolism.

Prediction of long-term response to recombinant human growth hormone in Turner syndrome: development and validation of mathematical models. KIGS International Board. Kabi International Growth Study.

M. Ranke, P. Chatelain, K. Albertsson-Wikland, 2000, The Journal of clinical endocrinology and metabolism.

The metabolic effects of short‐term administration of physiological versus high doses of GH therapy in GH deficient adults

P. Gluckman, D. Dunger, K. Ong, 2002, Clinical endocrinology.

Low dose linomide in Type I juvenile diabetes of recent onset: a randomised placebo-controlled double blind trial

C. Boitard, P. Landais, P. Chatelain, 1998, Diabetologia.

Transcriptomics and machine learning predict diagnosis and severity of growth hormone deficiency.

A. Stevens, P. Clayton, C. De Leonibus, 2018, JCI insight.

Pharmacogenomics Related to Growth Disorders

A. Stevens, D. Hanson, P. Clayton, 2013, Hormone Research in Paediatrics.

Congenital idiopathic growth hormone deficiency associated with prenatal and early postnatal growth failure. The International Board of the Kabi Pharmacia International Growth Study.

A. Gunn, P. Gluckman, G. Ambler, 1992, The Journal of pediatrics.

Clinical and Endocrine Characteristics in Atypical and Classical Growth Hormone Insensitivity Syndrome

M. Preece, M. Savage, P. Crock, 2001, Hormone Research in Paediatrics.

Phenotype: genotype relationships in growth hormone insensitivity syndrome.

M. Preece, S. Amselem, M. Ranke, 1997, The Journal of clinical endocrinology and metabolism.

Growth hormone insensitivity syndromes

M. Ranke, M. Savage, M. Ranke, 1995, Acta paediatrica (Oslo, Norway : 1992). Supplement.

A large-scale mutation search reveals genetic heterogeneity in 3M syndrome

D. Sillence, A. Munnich, J. Melki, 2009, European Journal of Human Genetics.

The effects of short-term administration of two low doses versus the standard GH replacement dose on insulin sensitivity and fasting glucose levels in young healthy adults.

P. Gluckman, D. Dunger, K. Ong, 2002, The Journal of clinical endocrinology and metabolism.

Children born with intra-uterine growth retardation (IUGR) or small for gestational age (SGA): long term growth and metabolic consequences.

P. Chatelain, 2000, Endocrine regulations.

Multiple Hormone Resistance in Short Children Born with Intrauterine Growth Retardation?

P. Chatelain, J. Chaussain, M. Nicolino, 1998, Hormone Research in Paediatrics.

GH deficiency status combined with GH receptor polymorphism affects response to GH in children

A. Valsesia, J. Wojcik, M. Maghnie, 2015, European journal of endocrinology.

Dose-dependent catch-up growth after 2 years of growth hormone treatment in intrauterine growth-retarded children. Belgian and French Pediatric Clinics and Sanofi-Choay (France).

P. Chatelain, M. Vanderschueren‐Lodeweyckx, L. Sagnard, 1994, The Journal of clinical endocrinology and metabolism.

Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth-hormone treatment

M. Ranke, P. Chatelain, K. Albertsson-Wikland, 2000, The Lancet.

A Randomized Phase 2 Study of Long-Acting TransCon GH vs Daily GH in Childhood GH Deficiency

P. Chatelain, J. Leff, V. Peterkova, 2017, The Journal of clinical endocrinology and metabolism.

Functional hypersomatotropism in small for gestational age (SGA) newborn infants.

G. Putet, P. Chatelain, D. Naville, 1989, The Journal of clinical endocrinology and metabolism.

Growth hormone treatment of short children born small for gestational age: metanalysis of four independent, randomized, controlled, multicentre studies

P. Chatelain, J. Chaussain, K. Albertsson-Wikland, 1996, Acta paediatrica (Oslo, Norway : 1992). Supplement.

Dramatic Early Postnatal Growth Failure in Children with Early Onset Growth Hormone Deficiency

P. Chatelain, 1991, Acta paediatrica Scandinavica. Supplement.

Diagnosis of Growth Hormone (GH) Deficiency and the Use of GH in Children with Growth Disorders

P. Hindmarsh, S. Bernasconi, N. Skakkebæk, 1999, Hormone Research in Paediatrics.

Liberation of immunoreactive somatomedin-C from its binding proteins by proteolytic enzymes and heparin.

D. Clemmons, P. Chatelain, J. V. Van Wyk, 1983, The Journal of clinical endocrinology and metabolism.

The paracrine role of Sertoli cells on Leydig cell function

P. Chatelain, P. Chatelain, J. Saez, 1992, Cell Biology and Toxicology.

Control of production of insulin-like growth factor I by pig Leydig and Sertoli cells cultured alone or together. Cell-cell interactions

P. Chatelain, D. Naville, J. Saez, 1990, Molecular and Cellular Endocrinology.

Differentiating effects of somatomedin-C/insulin-like growth factor I and insulin on Leydig and Sertoli cell functions.

P. Chatelain, D. Naville, C. Jaillard, 1988, Reproduction, nutrition, developpement.

Characterization and regulation of somatomedin-C/insulin-like growth factor I (Sm-C/IGF-I) receptors on cultured pig Leydig cells. Effects of Sm-C/IGF-I on luteotropin receptors and steroidogenesis.

P. Chatelain, C. Jaillard, J. Saez, 1987, European journal of biochemistry.

Regulation of gonadotropin receptors, gonadotropin responsiveness, and cell multiplication by somatomedin‐C and insulin in cultured pig Leydig cells

M. Bernier, P. Chatelain, J. Saez, 1986, Journal of cellular physiology.

Intra-Uterine Growth Retardation (IUGR) and Silver-Russell Syndrome (SRS): Etiological Aspects and Some Auxological Characteristics of Their Post-Natal Short Stature

P. Chatelain, M. Nicolino, O. Claris, 1994 .

Effect of in vitro action of serum proteases or exposure to acid on measurable immunoreactive somatomedin-C in serum.

P. Chatelain, K. Copeland, J. V. Van Wyk, 1983, The Journal of clinical endocrinology and metabolism.

Follow-Up of Three Years of Treatment with Growth Hormone and of One Post-Treatment Year, in Children with Severe Growth Retardation of Intrauterine Onset

P. Chatelain, J. Chaussain, M. Maes, 1996, Pediatric Research.

Changes in Insulin Sensitivity and Glucose Metabolism During Therapy with Recombinant Human Growth Hormone in Short Children Born Small For Gestational Age show a Negative Correlation with Baseline Measurements

R. Crabbé, P. Chatelain, M. von Holtey, 2008, Journal of pediatric endocrinology & metabolism : JPEM.

Erdheim-Chester disease: a primary macrophage cell disorder.

E. Brambilla, S. Lantuejoul, C. Brambilla, 1998, American journal of respiratory and critical care medicine.

Growth Hormone Treatment of Short Children Born Small for Gestational Age

L. Ibáñez, P. Chatelain, I. François, 1998, Trends in Endocrinology & Metabolism.

RU 486 ADMINISTRATION IN A CHILD WITH CUSHING'S SYNDROME

P. Chatelain, Y. Morel, R. François, 1987, The Lancet.

Surgical options in disorders of sex development (dsd) with ambiguous genitalia.

P. Chatelain, P. Mouriquand, M. Nicolino, 2010, Best practice & research. Clinical endocrinology & metabolism.

Insulin-like growth factor I stimulates human erythroid colony formation in vitro.

M. Claustres, P. Chatelain, C. Sultan, 1987, The Journal of clinical endocrinology and metabolism.

Treatment with growth hormone‐releasing hormone (GHRH) 1–44 in children with idiopathic growth hormone deficiency: a randomized double‐blind dose‐effect study

P. Chatelain, J. Boissel, M. Lièvre, 1992, Fundamental & clinical pharmacology.

Growth hormone (GH) response to a single intravenous injection of synthetic GH-releasing hormone in prepubertal children with growth failure.

P. Chatelain, J. Boissel, P. Sizonenko, 1987, The Journal of clinical endocrinology and metabolism.

Characterization of insulin-like growth factor I and insulin receptors on cultured bovine adrenal fasciculata cells. Role of these peptides on adrenal cell function.

P. Chatelain, A. Penhoat, C. Jaillard, 1988, Endocrinology.

The temporal relationship between the onset of type 1 diabetes and celiac disease: a study based on immunoglobulin a antitransglutaminase screening.

E. Levy, P. Chatelain, F. Bienvenu, 2004, Pediatrics.

In vitro regulation of pig Sertoli cell growth and function: effects of fibroblast growth factor and somatomedin-C.

P. Chatelain, C. Jaillard, J. Saez, 1987, Biology of reproduction.

Clinical features and endocrine status in patients with growth hormone insensitivity (Laron syndrome).

M. Preece, M. Savage, M. Ranke, 1993, The Journal of clinical endocrinology and metabolism.

Growth hormone treatment of short children born small for gestational age: growth responses with continuous and discontinuous regimens over 6 years.

H. Wollmann, F. de Zegher, P. Chatelain, 2000, The Journal of clinical endocrinology and metabolism.

Growth hormone therapy with three dosage regimens in children with idiopathic short stature. European Study Group Participating Investigators.

H. Delemarre-van de Waal, J. Wit, P. Chatelain, 1998, The Journal of pediatrics.

Near normalization of adolescent height with growth hormone therapy in very short children without growth hormone deficiency.

P. Chatelain, P. Bougnères, J. Chaussain, 1991, The Journal of pediatrics.

[Dual energy x-ray absorptiometry assessment of the bone mineral content and body composition during growth].

P. Chatelain, J. Bérard, P. Braillon, 2002, Journal de radiologie.

Therapeutic agents produced by genetic engineering: Quo vadis? The example of growth hormone and its releasing factor. Satellite symposium. Toulouse-Labège, May 29-30, 1985.

N. Ling, G. Sassolas, A. Caufriez, 1986, Hormone Research.

The Molecular Weight Forms of Rat Growth Hormone Secreted in Response to Growth Hormone-Releasing Factor

P. Chatelain, A. Baird, W. B. Wehrenberg, 1986, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

Effects of human pancreatic tumor growth hormone-releasing hormone (hpGRH1-44-NH2) on immunoreactive and bioactive plasma growth hormone in normal young men.

G. Sassolas, P. Chatelain, R. Cohen, 1984, The Journal of clinical endocrinology and metabolism.

Growth hormone treatment for childhood short stature and risk of stroke in early adulthood

P. Chatelain, M. Tauber, P. Bougnères, 2015, Neurology.

Autoantibodies and genetic factors associated with the development of Type 1 (insulin-dependent) diabetes mellitus in first degree relatives of diabetic patients

P. Chatelain, C. Thivolet, J. Orgiazzi, 1991, Diabetologia.

Islet cell and insulin autoantibodies in subjects at high risk for development of Type 1 (insulin-dependent) diabetes mellitus: the Lyon family study

P. Chatelain, C. Thivolet, L. Gebuhrer, 1988, Diabetologia.

Clinical studies with human growth hormone releasing factor in normal adults and patients

G. Sassolas, P. Chatelain, R. Cohen, 1986, Peptides.

Serum bone GLA‐protein in growth hormone deficient children

P. Delmas, P. Chatelain, L. Malaval, 1986, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Insulin-like growth factor I improves height in growth hormone insensitivity: two years' results.

M. Preece, M. Savage, M. Ranke, 1995, Hormone research.

Prenatal management of disorders of sex development.

L. Chitty, P. Chatelain, Y. Aigrain, 2012, Journal of pediatric urology.

Specific Receptors for IGF‐I on Cultured Bovine Adrenal Cells: Hormonal Regulation of IGF‐I Secretion by these Cells

P. Chatelain, A. Penhoat, D. Naville, 1988 .

Insulin-like growth factor I/somatomedin C action on 2-deoxyglucose and α-amino isobutyrate uptake in chick embryo fibroblasts

P. Chatelain, M. Vaubourdolle, L. Cynober, 1985 .

Growth hormone response to a bolus injection of 1-44 growth-hormone-releasing hormone in very short children with intrauterine onset of growth failure.

P. Chatelain, L. Sagnard, J. Job, 1990, Hormone research.

Evaluation of growth hormone bioactivity using the Nb2 cell bioassay in children with growth disorders

F. Locatelli, M. Autelli, L. Tatò, 1998, Journal of endocrinological investigation.

Assay of Growth Hormone Levels in Human Plasma using Commercial Kits: Analysis of Some Factors Influencing the Results

G. Sassolas, J. Souberbielle, P. Chatelain, 1990, Acta paediatrica Scandinavica. Supplement.

Long-Term Treatment of Growth Hormone Insensitivity Syndrome with IGF-I

M. Preece, M. Savage, M. Ranke, 1999, Hormone Research in Paediatrics.

Efficient purification of somatomedin-C/insulin-like growth factor I using immunoaffinity chromatography.

P. Chatelain, S. Chernausek, J. V. Van Wyk, 1985, Biochemical and biophysical research communications.

Somatomedin-C/insulin-like growth factor 1-like material secreted by porcine Sertoli cells in vitro: characterization and regulation.

P. Chatelain, D. Naville, J. Saez, 1987, Biochemical and biophysical research communications.

Effect of Recombinant Gonadotropin on Testicular Function and Testicular Sperm Extraction in Five Cases of NR0B1 (DAX1) Pathogenic Variants

P. Chatelain, N. Peretti, F. Tixier, 2022, Frontiers in Endocrinology.

Preoperative topical estrogen treatment versus placebo in 244 children with midshaft and posterior hypospadias.

P. Chatelain, P. Mouriquand, L. Remontet, 2020, The Journal of clinical endocrinology and metabolism.

Paracrine regulation of testicular function.

P. Chatelain, E. Tabone, M. Rivarola, 1987, Journal of steroid biochemistry.

Changes Over Time in Sex Assignment for Disorders of Sex Development

K. Lachlan, F. Darendeliler, A. Nordenström, 2014, Pediatrics.

Aetiological diagnosis of male sex ambiguity: a collaborative study

M. Forest, C. Teinturier, M. Fellous, 2001, European Journal of Pediatrics.

Endocrine screening in 32 consecutive patients with hypospadias.

M. Forest, P. Chatelain, P. Mouriquand, 2002, The Journal of urology.

Observation familiale de syndrome de Rothmund-Thomson. Observation en faveur de l'unicité du syndrome. Association à un ostéosarcome

G. Moulin, P. Chatelain, L. David, 1985 .

Deletion of mitochondrial DNA in a case of early-onset diabetes mellitus, optic atrophy, and deafness (Wolfram syndrome, MIM 222300).

A. Munnich, P. Rustin, A. Rötig, 1993, The Journal of clinical investigation.

Late prenatal dexamethasone and phenotype variations in 46,XX CAH: concerns about current protocols and benefits for surgical procedures.

P. Chatelain, A. Brac de la Perrière, P. Mouriquand, 2014, Journal of pediatric urology.

Undescended testis: comparison of two protocols of treatment with human chorionic gonadotropin. Effect on testicular descent and hormonal response.

M. Forest, J. Bertrand, P. Chatelain, 1988, Hormone research.

Genetic and molecular analysis of familial isolated growth hormone deficiency

P. Chatelain, C. Sultan, P. Sizonenko, 1993, Human Genetics.

Derivation and Validation of a Mathematical Model for Predicting the Response to Exogenous Recombinant Human Growth Hormone (GH) in Prepubertal Children with Idiopathic GH Deficiency

M. Ranke, P. Chatelain, K. Albertsson-Wikland, 1999 .

Optimization of Growth Hormone Dosing in Children Born Small for Gestational Age: An Open-Label, Randomized Study of Children during the Fourth Year of Therapy

P. Chatelain, M. Tauber, P. Berlier, 2012, Hormone Research in Paediatrics.

ACTH and angiotensin II regulation of insulin-like growth factor-I and its binding proteins in cultured bovine adrenal cells.

P. Chatelain, A. Penhoat, P. Leduque, 1991, Journal of molecular endocrinology.

Final height in idiopathic growth hormone deficiency: the KIGS experience

M. Ranke, M. Ranke, P. Chatelain, 1999, Acta paediatrica (Oslo, Norway : 1992). Supplement.

Regulation by growth factors og leydig cell differentiated functions

P. Chatelain, J. Saez, M. Vigier, 1991, The Journal of Steroid Biochemistry and Molecular Biology.

Normal Progression of Testicular Size in Boys with Idiopathic Short Stature and Isolated Growth Hormone Deficiency Treated with Growth Hormone: Experience from the KIGS

M. Ranke, P. Chatelain, E. Reiter, 2002, Hormone Research in Paediatrics.

Cell-cell communication in the testis.

P. Chatelain, J. Saez, H. Lejeune, 1991, Hormone research.

Growth hormone insensitivity syndrome (Laron syndrome): main characteristics and effects of IGF1 treatment.

M. Savage, P. Chatelain, J. Carel, 1996, Diabetes & metabolism.

Growth hormone to improve short bowel syndrome intestinal autonomy: a pediatric randomized open-label clinical trial.

F. Gottrand, P. Chatelain, L. Michaud, 2011, JPEN. Journal of parenteral and enteral nutrition.

Final height in Turner syndrome patients treated with growth hormone.

P. Czernichow, Y. Le Bouc, P. Chatelain, 1995, Hormone research.

Acromicric dysplasia: long term outcome and evidence of autosomal dominant inheritance

E. Zackai, A. Munnich, M. Polak, 2001, Journal of medical genetics.

Growth and differentiation of human keratinocytes on extracellular matrix

D. Schmitt, P. Chatelain, M. Faure, 2004, Archives of Dermatological Research.

Improvement in adult height after growth hormone treatment in adolescents with short stature born small for gestational age: results of a randomized controlled study.

P. Chatelain, J. Carel, J. Chaussain, 2003, The Journal of clinical endocrinology and metabolism.

Isolated prolactin deficiency in a woman with puerperal alactogenesis.

A. Ruokonen, P. Chatelain, A. Kauppila, 1987, The Journal of clinical endocrinology and metabolism.

Three years of GH treatment in Turner's syndrome: complex effect of GH dosage on growth parameters

P. Chatelain, J. Chaussain, A. Bertrand, 1996, Clinical endocrinology.

Long term results of growth hormone treatment in France in children of short stature: population, register based study

P. Chatelain, J. Carel, J. Chaussain, 1997, BMJ.

Prediction of Long-Term Response to Recombinant Human Growth Hormone in Turner Syndrome: Development and Validation of Mathematical Models

M. Ranke, P. Chatelain, K. Albertsson-Wikland, 2000 .

Recombinant human growth hormone for children born small for gestational age: Meta-analysis confirms the consistent dose-effect relationship on catch-up growth

R. Crabbé, M. Holtey, P. Chatelain, 2008, Journal of endocrinological investigation.

Growth curves for congenital adrenal hyperplasia from a national retrospective cohort

P. Chatelain, M. Nicolino, B. Riche, 2016, Journal of pediatric endocrinology & metabolism : JPEM.

Growth Hormone Therapy for Short Children Born Small for Gestational Age

P. Chatelain, A. Carrascosa, W. Sippell, 2007, Hormone Research in Paediatrics.

Short stature associated with intrauterine growth retardation: final height of untreated and growth hormone-treated children.

J. Coste, C. Bouvattier, P. Chatelain, 1998, The Journal of clinical endocrinology and metabolism.

Growth hormone treatment of short children born small for gestational age: reappraisal of the rate of bone maturation over 2 years and metanalysis of height gain over 4 years

P. Chatelain, J. Chaussain, K. Albertsson-Wikland, 1997, Acta paediatrica (Oslo, Norway : 1992). Supplement.

Validating genetic markers of response to recombinant human growth hormone in children with growth hormone deficiency and Turner syndrome: the PREDICT validation study

J. Wojcik, A. Stevens, P. Clayton, 2016, European journal of endocrinology.

A pharmacogenomic approach to the treatment of children with GH deficiency or Turner syndrome

A. Stevens, P. Clayton, C. Deal, 2013, European journal of endocrinology.

Efficacy and Safety of Growth Hormone Treatment in Children with Prior Craniopharyngioma: An Analysis of the Pharmacia and Upjohn International Growth Database (KIGS) from 1988 to 1996

M. Ranke, M. Ranke, P. Chatelain, 1998, Hormone Research in Paediatrics.

Proliferative retinopathy in a woman with growth hormone deficiency and diabetes mellitus.

P. Chatelain, C. Thivolet, P. Fournier, 1990, British medical journal.

Partial androgen insensitivity with phenotypic variation caused by androgen receptor mutations that disrupt activation function 2 and the NH2- and carboxyl-terminal interaction

M. Forest, F. S. French, E. Wilson, 2004, Mechanisms of Ageing and Development.

G. Sassolas, P. Chatelain, 1986 .

Predicting the response to recombinant human growth hormone in Turner syndrome: KIGS models

M. Ranke, P. Chatelain, D. Price, 1999, Acta paediatrica.

Glutamic acid decarboxylase (GAD) autoantibodies are additional predictive markers of Type 1 (insulin-dependent) diabetes mellitus in high risk individuals

W. Scherbaum, J. Petersen, P. Chatelain, 1992, Diabetologia.

Clinical Spectrum of the Syndrome of Growth Hormone Insensitivity

M. Ranke, M. Preece, P. Chatelain, 1991, Acta paediatrica Scandinavica. Supplement.

Clinical Features and Endocrine Status in Patients with Growth Hormone Insensitivity

M. Preece, P. Chatelain, A. Cotterill, 1993 .

Increase of circulating insulin-like growth factor-I in chronic renal failure is reduced by low-protein diet.

B. Beaufrère, P. Chatelain, M. Joly, 1992, Mineral and electrolyte metabolism.

41 EUROPEAN COLLABORATIVE STUDY ON THE EFFECT OF SYNTHETIC I-44 GROWTH-HORMONE-RELEASING-FACTOR(GRF) ON PLASMA GROWTH HORMONE(GH) IN PREPUBERTAL CHILDREN WITH GROWTH FAILURE. (GRF European Multicenter Study)

P. Chatelain, 1985, Pediatric Research.

Deletion of mitochondrial DNA in a case of early-onset diabetes mellitus, optic atrophy and deafness (DIDMOAD, Wolfram syndrome)

A. Munnich, P. Rustin, A. Rötig, 1993, Journal of Inherited Metabolic Disease.

Leydig cell and extracellular matrix effects on Sertoli cell function: biochemical and morphologic studies.

P. Chatelain, J. Reventós, J. Saez, 1989, Journal of andrology.

Growth Hormone Insensitivity Syndrome (GHIS): Clinical Presentation and Effects of Treatment with Recombinant Human Insulin-like Growth Factor I (rhIGF-I) European Experience

M. Preece, M. Savage, M. Ranke, 1994 .

THERAPEUTIC RESPONSE TO RECOMBINANT IGF-1 IN THIRTY TWO PATIENTS WITH GROWTH HORMONE INSENSITIVITY

M. Preece, M. Savage, M. Ranke, 1993, Pediatric Research.

The Potential of Prediction Models Based on Data from KIGS as Tools to Measure Responsiveness to Growth Hormone

M. Ranke, P. Chatelain, K. Albertsson-Wikland, 2004, Hormone Research in Paediatrics.

Treatment of growth hormone insensitivity syndrome with insulin‐like growth factor I: long‐term results of the European multicentre study

P. Chatelain, R. Rosenfeld, M. Savage, 1999 .

Effect of purified somatomedins on thymidine incorporation into lectin-activated human lymphocytes.

A. Salvatoni, P. Chatelain, A. Repellin, 1983, Acta endocrinologica.

Dual energy X‐ray absorptiometry of the hand and wrist–a possible technique to assess skeletal maturation: methodology and data in normal youths

P. Chatelain, A. Serban, PM Braillon, 1998, Acta paediatrica.

Evaluation of gonadal function in 107 intersex patients by means of serum antimüllerian hormone measurement.

M. Forest, P. Czernichow, F. Baş, 1999, The Journal of clinical endocrinology and metabolism.

Studies of a cohort of 46,XY with DSD including steroid biosynthesis deficiencies.

P. Chatelain, M. Nicolino, Y. Morel, 2011, Advances in experimental medicine and biology.

Growth Hormone Therapy for Short Children Born Small for Gestational Age

P. Chatelain, A. Ferrández-Longás, G. Bona, 2007, Hormone Research in Paediatrics.

Comparison of 24 Hour Growth Hormone Secretion and Pharmacological Tests in 38 Children with Short Stature

P. Chatelain, M. Tauber, C. Pienkowski, 1987 .

Growth hormone treatment for childhood short stature and risk of stroke in early adulthood

R. Santen, J. Kopchick, M. Geffner, 2015, Neurology.